Limits...
Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.

Trendowski M, Zoino JN, Christen TD, Acquafondata C, Fondy TP - Transl Oncol (2015)

Bottom Line: We also examine the effects of cytochalasin B against several other murine neoplastic cell lines (Lewis lung, LA4, B16F10, and M5076).Finally, we examine a potential mechanism of the antimetastatic activity of cytochalasin B by observing the effects of the agent on the secretion of N-acetylglucosaminidase (GlcNACase) by B16BL6 and B16F10 murine melanomas in vitro.These effects were comparable to intraperitoneally administered doxorubicin. 4) Low concentrations of cytochalasin B inhibit the secretion of GlcNACase, indicating that cytochalasin B may inhibit metastatic progression by mechanisms not directly associated with its influence on cell adhesion and motility.

View Article: PubMed Central - PubMed

Affiliation: Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA. Electronic address: mrtrendo@syr.edu.

No MeSH data available.


Related in: MedlinePlus

Effects of cytochalasin B administered once as a 100-mg/kg s.c. dose on potentiating long-term survival in mice challenged with various solid tumors. Mice were challenged i.d. with M109 lung carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, or M5076 sarcoma. In each challenge, the survival of tumor-bearing mice treated with cytochalasin B (denoted by CB) was significantly different than the vehicle-only–treated group (denoted by V); P < .05, as assessed by a Cox-Mantel test. There were 10 mice for all cohorts.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562975&req=5

f0020: Effects of cytochalasin B administered once as a 100-mg/kg s.c. dose on potentiating long-term survival in mice challenged with various solid tumors. Mice were challenged i.d. with M109 lung carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, or M5076 sarcoma. In each challenge, the survival of tumor-bearing mice treated with cytochalasin B (denoted by CB) was significantly different than the vehicle-only–treated group (denoted by V); P < .05, as assessed by a Cox-Mantel test. There were 10 mice for all cohorts.

Mentions: Cytochalasin B administered s.c. as a 100-mg/kg dose on day 1 appeared to have marked antineoplastic activity against most of the solid tumor challenges (Figure 4), as a significant proportion of the mice lived at least 53 days after the initial tumor challenge: M109 lung carcinoma (4/10 mice), Lewis lung carcinoma (5/10 mice), LA4 lung adenocarcinoma (6/10 mice), and B16F10 melanoma (4/10 mice). Although 100 mg/kg cytochalasin B s.c. significantly prolonged the survival of mice challenged with M5076 sarcoma in comparison with the vehicle-only treated mice, all mice in this cohort were dead by day 30; the treatment was unable to produce any long-term survivors at day 53 (0/10 mice), and all mice were dead by day 44 (Figure 4).


Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.

Trendowski M, Zoino JN, Christen TD, Acquafondata C, Fondy TP - Transl Oncol (2015)

Effects of cytochalasin B administered once as a 100-mg/kg s.c. dose on potentiating long-term survival in mice challenged with various solid tumors. Mice were challenged i.d. with M109 lung carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, or M5076 sarcoma. In each challenge, the survival of tumor-bearing mice treated with cytochalasin B (denoted by CB) was significantly different than the vehicle-only–treated group (denoted by V); P < .05, as assessed by a Cox-Mantel test. There were 10 mice for all cohorts.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562975&req=5

f0020: Effects of cytochalasin B administered once as a 100-mg/kg s.c. dose on potentiating long-term survival in mice challenged with various solid tumors. Mice were challenged i.d. with M109 lung carcinoma and s.c. with Lewis lung carcinoma, LA4 lung adenocarcinoma, B16F10 melanoma, or M5076 sarcoma. In each challenge, the survival of tumor-bearing mice treated with cytochalasin B (denoted by CB) was significantly different than the vehicle-only–treated group (denoted by V); P < .05, as assessed by a Cox-Mantel test. There were 10 mice for all cohorts.
Mentions: Cytochalasin B administered s.c. as a 100-mg/kg dose on day 1 appeared to have marked antineoplastic activity against most of the solid tumor challenges (Figure 4), as a significant proportion of the mice lived at least 53 days after the initial tumor challenge: M109 lung carcinoma (4/10 mice), Lewis lung carcinoma (5/10 mice), LA4 lung adenocarcinoma (6/10 mice), and B16F10 melanoma (4/10 mice). Although 100 mg/kg cytochalasin B s.c. significantly prolonged the survival of mice challenged with M5076 sarcoma in comparison with the vehicle-only treated mice, all mice in this cohort were dead by day 30; the treatment was unable to produce any long-term survivors at day 53 (0/10 mice), and all mice were dead by day 44 (Figure 4).

Bottom Line: We also examine the effects of cytochalasin B against several other murine neoplastic cell lines (Lewis lung, LA4, B16F10, and M5076).Finally, we examine a potential mechanism of the antimetastatic activity of cytochalasin B by observing the effects of the agent on the secretion of N-acetylglucosaminidase (GlcNACase) by B16BL6 and B16F10 murine melanomas in vitro.These effects were comparable to intraperitoneally administered doxorubicin. 4) Low concentrations of cytochalasin B inhibit the secretion of GlcNACase, indicating that cytochalasin B may inhibit metastatic progression by mechanisms not directly associated with its influence on cell adhesion and motility.

View Article: PubMed Central - PubMed

Affiliation: Department of Biology, Syracuse University, 107 College Place, Syracuse, NY 13244, USA. Electronic address: mrtrendo@syr.edu.

No MeSH data available.


Related in: MedlinePlus